STUDresearch · Non-peptide
Quercetin
Also known as
Quercetin dihydrate · Quercetin aglycone · Quercetin phytosome · Quercetin Phytosome™ · Quercefit · QuerceFit® · EMIQ · Enzymatically modified isoquercitrin · Isoquercetin · 3,3′,4′,5,7-pentahydroxyflavone · SOPHORIN (historical plant-flavonoid context) · D+Q (with dasatinib)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral
Senolytic & longevity compounds
Systemic oral flavonol used in supplement and D+Q discussions; food, aglycone, glycoside and enhanced-absorption forms are not equivalent.
What people say
Quercetin is an oral plant flavonol in foods and concentrated supplements. Plain aglycone, food glycosides, phytosome products and EMIQ are not interchangeable; D+Q adds prescription dasatinib.
Doses people talk about
Descriptive accounts, not guidance. Form affects exposure; D+Q includes a prescription drug and is not an everyday solo-quercetin band.
How it may feel
Usually discussed without a stimulant-like effect, but 500 mg accounts conflict: slight benefit/constipation, headache or digestive symptoms, and one acute itching/numbness/congestion report. D+Q reports cannot isolate quercetin.
Solo supplement reports500 mg oral
Individual reports ranged from slight benefit/constipation to acute or persistent adverse symptoms.
D+Q report AQ 1,200 mg + D 100 mg daily for 2 days
Repeated every other month; later joint improvement was confounded by rapamycin and other changing supplements.
D+Q report BQ 1,500 mg + D 100 mg on reported dosing days
Author wrote “three days in a row for three weeks” every four to five months for over two years; total dose-days were ambiguous, and no noticeable effect was reported.
Half-life & effect duration
- Half-life in the body
- Oral aglycone capsule · studyAbout 3.5 hours
- Oral food / glycosides · plasma conjugatesAbout 11 hours
- IV aglycone · older estimatesAbout 0.7–2.4 hours
- Felt duration people report
- Solo-use accountsSlight improvement or constipation over a month; symptoms within minutes lasting hours in another account
- D+Q accountsNo noticeable effect or long-term joint improvement amid other compounds
Cycles people discuss
Use splits into ongoing daily or seasonal supplements and intermittent D+Q pulses. One author reported two days every other month; another described “three days in a row for three weeks” every four to five months, leaving total dose-days ambiguous. Neither is validated.
Timing
Timing depends on use context: ongoing or seasonal solo supplements and intermittent D+Q pulses are different patterns. With-food use is discussed for GI comfort and absorption, but empty-stomach use is not a standardized research requirement.
Stacks
D+Q pairs quercetin with prescription dasatinib; allergy/immune products often add zinc, vitamin C or bromelain, while polyphenol mixes add fisetin, resveratrol or curcumin. Combinations prevent attribution.
Watch for
GI upset: Nausea, stomach discomfort, cramping, loose stools — top dose-related complaint, especially high single doses or empty stomach.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Human oral PK reports differ by formulation and analyte: 3.5 hours in one aglycone-capsule study and about 11 hours for plasma conjugates after glycoside/food forms.
Moon et al. used 500 mg TID and a model with enterohepatic re-entry; Graefe et al. compared food/glycoside forms in 12 healthy volunteers. The values remain separate.
Small studies, differing forms, repeated versus crossover exposure and differing measured species prevent a universal half-life; phytosome and EMIQ were not measured.
- Moon et al. — Quercetin pharmacokinetics in humans (opens in a new tab)Subjects received 500 mg three times daily; aglycone and conjugates were assayed, and the population model reported average terminal quercetin half-life 3.5 hours with re-entry peaks.Specific capsule regimen/model/analytes; not one value for food glycosides, phytosomes, EMIQ or every conjugate.
- Graefe et al. — Pharmacokinetics and bioavailability of quercetin glycosides in humans (opens in a new tab)Twelve healthy volunteers received onion glucosides, quercetin-4-prime-O-glucoside, rutin or buckwheat tea; plasma conjugates had about an 11-hour terminal half-life.Small crossover study of food/glycoside forms and conjugates, not a universal unchanged-parent or felt-effect value.
Felt duration people report
The inspected accounts do not establish a consistent felt onset or duration for quercetin.
Solo 500 mg reports ranged from slight improvement/constipation over a month to acute symptoms within minutes lasting hours. D+Q users reported either no noticeable effect or long-term joint improvement amid other compounds.
Anonymous reports, self-selected illness communities, unverified products and combination use prevent causal timing or prevalence estimates.
- Reddit r/HistamineIntolerance — Quercetin (opens in a new tab)Accounts included 500 mg with slight benefit/constipation over about a month, tension headache, and a same-author update with nausea, diarrhea, headache and numbness.Anonymous, uncontrolled, medically selected community; brands, diagnoses and co-exposures varied.
- Reddit r/HistamineIntolerance — Quercetin causes huge histamine attack (opens in a new tab)Author reported itching, tongue numbness, esophageal congestion and severe headache within minutes of 500 mg quercetin plus zinc with food, lasting hours.Single anonymous combination-product report without clinical confirmation; cannot isolate quercetin.
- Rapamycin.news — Has anyone used D+Q as a senolytic? (opens in a new tab)One user described D100+Q1500 on dosing days as “three days in a row for three weeks” every 4–5 months for over two years, with no noticeable effect; wording leaves total dose-days ambiguous. Another described D100+Q1200 for two days every other month and later joint improvement amid other compounds.Self-reports with prescription exposure, changing stacks and no comparator; cannot isolate Q or validate senolysis/scheduling.
What people say
- Immune / URTI season: Community logs of fewer or milder seasonal complaints in quercetin ± zinc ± vitamin C stacks; formal URTI prevention data mixed by dose and population. forum
- Allergy / histamine: Less seasonal itch/sneeze/nasal load in pollen windows; mast-cell-stabilizer narrative is popular but largely preclinical + anecdote. forum
- Inflammation / recovery: Soft “lower background noise,” easier training weeks, less “inflamed” feel on daily use — confounded and subjective. anecdote
- URTI plasma study context: Multi-week oral 500–1,000 mg/day raised plasma quercetin with few reported sides in studied cohorts — exposure proof more than cure claim. trial
- D+Q human pilot (kidney): Hickson open-label: oral dasatinib 100 mg + quercetin 1,000 mg for 3 days in diabetic kidney disease; adipose senescence and inflammation markers fell on biopsy follow-up (small N). trial
- D+Q IPF / function: Justice open-label and later IPF work used D 100 mg + Q ~1,000–1,250 mg/day for 3 consecutive days/week-style pulses; physical-function signals discussed, not a approved IPF therapy. trial
- D+Q AD / CSF: Early Alzheimer’s feasibility cycles (e.g. 100 mg D + 1,000 mg Q, 2 days on / ~14 days off) reported dasatinib in CSF more readily than quercetin; safety/tolerability focus, not proven cognitive reverse. trial
- Animal D+Q: Rodent models cut senescent-cell burden and age-tissue endpoints (including long-term weekly D+Q disc-health work) — primary mechanistic backbone for bro protocols. animal
- Uric acid / metabolic: Phytosome and plain-quercetin cohorts discuss plasma uric-acid reductions (e.g. multi-week ~500 mg/day or phytosome regimens) and occasional lipid talk; not a gout cure. trial
- RA / joint comfort pilot: Small human work at ~500 mg/day discussed less morning stiffness/pain after activity in women with rheumatoid arthritis — limited generalizability. trial
- Antioxidant “why”: Preclinical ROS, NF-κB, and pathway papers are the usual mechanism cites for daily use. lab
- vs food: Typical diet may supply only ~5–40+ mg/day; supplemental hundreds–thousands of mg are a different exposure class. trial
Doses people talk about
- Everyday oral and inspected 500 mg reports: The preserved consumer band is ~500–1,000 mg/day. In histamine-intolerance threads, individual 500 mg reports ranged from slight benefit and constipation to headache, reflux or marked acute symptoms. forum
- Split daily: 250–500 mg BID with meals is a frequent pattern for steadier coverage and fewer GI complaints than one large bolus. forum
- Upper daily consumer talk: Some product/education sources discuss up to ~1,000 mg twice daily short-term; mild headache/GI/tingling risk rises with multi-gram days. forum
- Inspected D+Q community pulses plus broader copy: One user reported D 100 mg + Q 1,500 mg on dosing days described as “three days in a row for three weeks” every 4–5 months; the post leaves the total number of dose-days ambiguous. Another reported D 100 mg + Q 1,200 mg daily for 2 days every other month. Broader posts often repeat Q 1,000 mg for 2–3 days. These are reports, not validated schedules. forum
- Absorption hacks: With dietary fat; bromelain co-admin (popular combo products; some sources claim large relative absorption boosts — human magnitude debated); piperine/Bioperine for UGT/metabolism chatter; vitamin C often co-formulated (stability/uptake lore). forum
- Do not confuse: Continuous daily 500–1,000 mg antioxidant habit ≠ intermittent multi-gram D+Q senolytic weekend math. forum
- Label trap: Aglycone, dihydrate, glycoside, EMIQ, and phytosome milligrams are not interchangeable exposure units — compare forms by brand PK claims and elemental quercetin content, not bottle front-panel only. forum
- Food baseline: Roughly ~5–40 mg/day (higher with onion-heavy diets) — not equivalent to supplemental capsules. trial
- Study range breadth: Examine-style summaries note studied intakes roughly ~30 mg to ~3,000 mg/day depending on trial — not a single “correct” dose. trial
- Short-course safety window often cited: ~500 mg BID for up to ~12 weeks appears in consumer safety summaries as a commonly referenced short-term band — not a longevity license. trial
- Phytosome PK claim: Riva et al. human PK: Quercetin Phytosome up to ~20-fold higher oral bioavailability vs unformulated quercetin; 250 mg and 500 mg phytosome doses studied vs plain 500 mg. trial
- Phytosome metabolic trials: Examples include ~250 mg phytosome TID with meals for 90 days (metabolic-health NCT-style design) and multi-week ~500 mg/day phytosome COVID-era/prevention cohorts — designs vary. trial
- Uric-acid phytosome talk: Multi-week to 90-day phytosome regimens (e.g. ~400–500 mg product-level, sometimes BID) appear in hyperuricemia discussion papers. trial
- EMIQ / activated quercetin: Marketed as ~17× (human) to ~40× (animal Cmax) higher exposure vs plain quercetin; consumer capsules often ~100–170 mg EMIQ-range with vitamin C — not 1:1 with 500 mg aglycone bottles. trial
- Isoquercetin / onion glycoside angle: Food-form glucosides (isoquercetin-rich onion) absorb better than some aglycone supplements in classic Hollman-era work (~52% vs ~24% absorption contrast often cited). trial
- D+Q Hickson (DKD pilot): Dasatinib 100 mg + quercetin 1,000 mg oral daily for 3 consecutive days (single short course in the published pilot). trial
- D+Q Justice / IPF-style: Dasatinib 100 mg/day + quercetin 1,250 mg/day for 3 consecutive days per week × multiple weeks (e.g. three weeks of 3-on / rest pattern; nine dosing days in one design). trial
- D+Q AD-style cycles: Often 100 mg D + 1,000 mg Q for 2 consecutive days every ~14–15 days × multiple cycles (e.g. six cycles / ~12 weeks in STOMP-AD-style talk). trial
- Q form in some IPF work: At least one protocol notes quercetin phytosome (e.g. Thorne / Sophora japonica–phosphatidylcholine complex) as the Q product at ~1,250 mg/day pulse — form is not always plain aglycone. trial
- Framing: Discussed research and community ranges only — not medical advice, not a prescription, not a consumption guide. forum
- Phytosome / Quercefit label: Vendor and PK context often ~250 mg once or twice daily of complex; pure quercetin inside the complex is lower than total complex weight (e.g. ~100 mg quercetin in ~250 mg Quercefit-type complex is discussed in product literature). trial
- D+Q Nambiar IPF RCT arm: Same ballpark D 100 mg + Q 1,250 mg, three consecutive days/week for three weeks vs placebo. trial
How it may feel
- Day 0 expectations: Most users report little psychoactive or stimulant feel; it is not a “buzz” compound. forum
- Inspected 500 mg reports: One user described slight benefit then constipation over about a month; others reported headache, reflux/gas, or nausea/diarrhea, and one account described itching, tongue numbness, congestion and severe headache within minutes. forum
- Week 1 immune stack: Common “start at first sniffle / high pollen” window for Q+zinc+C; attribution confounded by rest and other meds. forum
- Weeks 1–2 checkpoint: Decision point to switch form (plain → phytosome/EMIQ), add fat/bromelain, or abandon for non-response. forum
- Weeks 3–4 daily habit: Steady antioxidant/immune habit phase; non-responders usually stop or change brand rather than endless escalate past ~1 g plain. forum
- D+Q pulse days: Feel is often dominated by dasatinib (GI, fatigue, headache) more than quercetin; quercetin alone is quieter. forum
- Off-week after D+Q: Minimal day-to-day “on drug” feel; longevity crowd judges labs, function, and subjective recovery weeks later, not same-day euphoria. forum
- Months 2–3: Split into either low-friction daily polyphenol habit or scheduled senolytic weekends/monthly pulses — two different mental models. forum
Cycles people discuss
- Daily antioxidant / immune habit: Open-ended weeks to months, often no formal off-cycle if GI and drug list stay quiet. forum
- Seasonal blocks: ~4–12 weeks spanning pollen season, winter immune season, or travel — then pause or drop to food-only. forum
- Short URTI “onset” use: Some protocols discuss ~7–14 days higher intensity at first symptoms alongside zinc/C — community practice, not a universal RCT schedule. forum
- Why off in D+Q: Hit-and-run clearance narrative — clear senescent cells, then wait while new ones reaccumulate slowly; also limits chronic dasatinib kinase-inhibitor exposure. forum
- Re-runs: Seasonal immune blocks or quarterly/monthly longevity calendars; healthy long-term stack safety still thin. forum
- Daily Q + pulse Fisetin/D+Q calendars: Some longevity logs keep low daily Q and add separate fisetin or full D+Q weekends — schedules conflict across blogs; no single standard. forum
- D+Q pulse model: 2–3 consecutive on-days, then ~2–5+ weeks off (or every ~14–15 days in some AD pilots; monthly 3-day blocks in other copies). trial
- Multi-cycle research templates: IPF-style three weeks of weekly 3-day pulses; AD-style six biweekly 2-day cycles; kidney pilot single 3-day course with later tissue readouts. trial
Timing
- Daily/BID logic: Incomplete single-dose coverage + short free parent → continuous daily or twice-daily use for immune/antioxidant goals. forum
- With food: Common for GI comfort and lipid-assisted absorption; empty-stomach not a standardized research requirement. forum
- Parent vs metabolites: Free plasma quercetin is short-lived; conjugated metabolites persist longer — “half-life” quotes mix parent and total quercetin. trial
- Oral PK is analyte- and form-specific: A 500 mg TID aglycone study reported an average terminal quercetin t½ of 3.5 h; a 12-person glycoside/food study reported about 11 h for measured plasma conjugates. This does not support one universal 11–28 h value. trial
- IV contrast: IV aglycone terminal half-life reported much shorter (~0.7–2.4 hours in older IV work) — oral community math should not copy IV numbers. trial
- Tmax / peak: Hours post-dose depending on form and food; not a minutes-scale stimulant peak. trial
- Senolytic timing logic: Brief multi-day D+Q pulse is enough in the research narrative; weeks off while senescent burden is assumed to reaccumulate slowly. trial
- Inter-subject chaos: Plasma AUC and Cmax after the same oral mg can vary several-fold (β-glucosidase, UGT/SULT/COMT differences discussed). trial
- Form ≠ same exposure: Phytosome and EMIQ change Cmax/AUC vs plain at equal labeled “quercetin” mg; equal bottle numbers are not equal blood exposure. trial
- Elimination talk: Substantial clearance by ~24–48 hours post-ingestion in PK narratives; urinary recovery of unchanged quercetin is low. trial
- CSF note (D+Q AD work): Dasatinib detected in CSF more readily than quercetin in early sampling windows — relevant to brain-aging stack hype vs actual Q CNS exposure. trial
More on what it is
- Why people search it: Three big lanes — seasonal immune/allergy stacks, antioxidant “daily polyphenol,” and the quercetin half of research D+Q senolytic pulses. forum
- Mechanism talk: ROS scavenging, anti-inflammatory pathway chatter, mast-cell/histamine moderation, and BCL-family synergy with dasatinib against senescent-cell survival nets. forum
- What it is: Plant flavonol (onions, apples, berries, tea, Sophora japonica extract); common oral capsule/powder supplement far above food intake. trial
- Solo senolytic honesty: Mouse screens often rank quercetin weaker alone than fisetin; longevity culture mostly uses it with dasatinib, not as a proven single-agent zombie-cell drug. animal
- Evidence posture: Human pilots exist (D+Q markers, phytosome PK, small metabolic/immune cohorts); large longevity RCTs proving lifespan or universal senolysis are still missing. trial
- Bioavailability problem: Plain oral aglycone absorbs poorly; phytosome/lecithin, EMIQ/isoquercetin, fat meals, bromelain, and piperine are the constant form fights. trial
- What it is not: Not a solo prescription senolytic, not a steroid, not an approved anti-aging drug, and not interchangeable mg-for-mg across aglycone vs dihydrate vs glycoside vs phytosome labels. trial
Stacks
- D+Q+F: Some longevity logs add fisetin as a third flavonoid on pulse weekends. forum
- Immune season trinity: Quercetin + zinc + vitamin C (± vitamin D) — pandemic-era and cold-season staple stack. forum
- Zinc ionophore lore: Community claims quercetin helps zinc intracellular delivery; mechanistic popularity exceeds clean clinical proof. forum
- Allergy / absorption combo: Quercetin + bromelain (± vitamin C) — retail default for “high absorption” and seasonal comfort. forum
- Piperine partner: Black-pepper extract for UGT/metabolism and polyphenol durability talk — drug-interaction caution rises with piperine. forum
- Flavonoid neighbor calendars: Alongside or alternating with fisetin pulses; also luteolin/apigenin in “natural antihistamine” stacks. forum
- Metabolic adjuncts: Sometimes berberine or other lipid/uric-acid neighbors when metabolic markers are the focus. forum
- Longevity backbone adjacency: Listed near rapamycin, metformin, NMN/NR programs — co-timing is confounded lifestyle stacking, not proven synergy. forum
- D+Q: Dasatinib + quercetin — the top named research senolytic combo; almost all human senolytic pilot talk for Q is as this pair. trial
- vs fisetin bro framing: Fisetin often cast as stronger solo senolytic (2018 mouse screen); quercetin cast as broader antioxidant + D+Q heritage. forum
- Polyphenol mix: Resveratrol, curcumin, EGCG in multi-polyphenol bottles — permeability/competition nuances in vitro, messy in real stacks. lab
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- GI upset: Nausea, stomach discomfort, cramping, loose stools — top dose-related complaint, especially high single doses or empty stomach. forum
- Headache / extremity tingling: Minority of logs and safety summaries at higher daily totals (often discussed around multi-hundred-mg to gram-range use). forum
- Kidney disease populations: Educational sources often advise against unsupervised high-dose use when kidneys are already compromised. forum
- Piperine amplifies interaction risk: Absorption boosters that inhibit metabolism can change co-drug levels — stack caution, not free optimization. forum
- Pregnancy / lactation: Not a settled safe high-dose window; general avoid-unsupervised-supplement posture in educational sources. forum
- Thyroid / energy noise: Occasional anecdotes of energy or thyroid-adjacent feels; no clean consensus effect size. anecdote
- Caffeine sensitivity lore: Some consumer guides lump caffeine-sensitive users as a caution group — soft evidence, still appears in who-should-not lists. forum
- Product quality: Bulk gray powder and under-dosed retail bottles risk mislabel, oxidation, and contamination; third-party testing is the practical filter. forum
- Label math risk: Switching from plain 1,000 mg to “20× phytosome” without understanding complex weight can either underdose exposure goals or create false confidence. forum
- Not risk-free long-term: Short-trial tolerance ≠ proven lifelong multi-gram or continuous high-dose stack safety; longevity self-experimenters often under-monitor. forum
- Generally mild oral AE profile in short trials: Published intervention reviews note adverse effects are uncommon and usually mild when they occur — not a free pass for megadoses. trial
- Kidney caution (oral vs IV): High-dose IV quercetin has nephrotoxicity history; oral high-dose concern is lower but predamaged-kidney enhancement of nephrotoxicity is flagged in animal/safety reviews — extra care if eGFR is impaired. trial
- Drug interactions (CYP/transporters): Models and clinical interaction lists flag CYP3A4 and P-gp/MDR-related effects; examples discussed include altered levels of various CYP3A4 substrates, cyclosporine bioavailability shifts in animal work, and caution with many Rx classes. trial
- Named interaction themes: Warfarin/anticoagulant caution, digoxin co-admin avoid/monitor language in some references, quinolone antibiotic talk, and “tell your clinician about all Rx” as the default. trial
- D+Q risk driver: Monitoring burden, cytopenias, fluid retention, pleural effusion risk, and infection/bleed themes are dominated by dasatinib, not quercetin alone — still not “Q makes D safe.” trial
- Tumor / estrogen-dependent cancer caution (animal signal): Safety reviews mention theoretical tumor-promotion signals in some animal contexts (including estrogen-dependent models) — sparse human clarity, listed as a research caution. animal
- Research-only framing: Discussed doses and stacks are for education and literature mapping — not instructions to take any drug or supplement. forum
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.